Pegfilgrastim is a Recombinant Protein owned by Amgen, and is involved in 77 clinical trials, of which 70 were completed, 5 are ongoing, and 2 are planned.

Pegfilgrastim binds to the G-CSF receptor. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Pegfilgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Pegfilgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, pegfilgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase. Neulasta is a white blood cell booster to help support your natural defenses and help reduce the risk of infection in patients with some tumors receiving strong chemotherapy. Granulocyte colony-stimulating factor (G-CSF) receptor (GcR) mediates growth and differentiation signals in the granulocyte/monocyte lineage of hematopoietic cells.

The revenue for Pegfilgrastim is expected to reach a total of $3.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Pegfilgrastim NPV Report.

Pegfilgrastim is currently owned by Amgen. Kyowa Kirin is the other company associated in development or marketing of Pegfilgrastim.

Pegfilgrastim Overview

Pegfilgrastim (Neulasta/ Ristempa/ G-Lasta/ Neupopeg/ Neulastim, Granulokine/ Tezmota) is a covalent conjugate of recombinant human granulocyte colony stimulating factor G-CSF with polyethylene glycol (PEG) molecule. It is formulated as pegylated injectable solution for subcutaneous route of administration. Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Ristempa is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). Neulasta is indicated to increase survival in  patients  acutely exposed to myelosuppressive doses of radiation.

Kyowa Kirin Overview

Kyowa Kirin, a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY352,246 million for the fiscal year ended December 2021 (FY2021), an increase of 10.6% over FY2020. In FY2021, the company’s operating margin was 17%, compared to an operating margin of 15.9% in FY2020. In FY2021, the company recorded a net margin of 14.9%, compared to a net margin of 14.8% in FY2020. The company reported revenues of JPY98,504 million for the third quarter ended September 2022, an increase of 1% over the previous quarter.

Quick View – Pegfilgrastim

Report Segments
  • Innovator (NME)
Drug Name
  • Pegfilgrastim
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Hematological Disorders
  • Toxicology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.